Inoviem Scientific is a bioanalytical Contract Research Organization (CRO) that specializes in providing precision and insight into a compound's clinical Mode of Action (MoA) for efficient drug development. With a focus on translational pharmacology, Inoviem offers a range of services tailored to the needs of drug discovery, preclinical, and clinical development. Their expertise lies in the utilization of proprietary label-free technologies, NPOT® and PIMS®, which enable the analysis of drug-target interactions directly on non-modified human tissue.

This breakthrough approach allows for the identification and validation of targets, stratification of patient groups, and biomarker identification. By working closely with big pharma, biotechs, and research institutions, Inoviem's scientific team contributes to the field of pharmacology, aiming to reduce side effects, increase therapeutic effectiveness, and personalize medicine. Their commitment to innovation, excellence, and respect for life ensures that they remain at the forefront of drug development.

Headquartered in France, Inoviem Scientific is dedicated to advancing the quality of life and well-being of individuals through their cutting-edge technologies and solutions